Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1A46 in R/R CD20 and/or CD19-positive B-NHL (Phase I/II, China)
CTR20232077Phase 2Terminated
- Sponsor
- EpimAb Biotherapeutics
- Start
- Jul 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 1A46 in mature B-cell lymphoma, sponsored by EpimAb Biotherapeutics. Started Jul 2023; status: terminated.
02
Drugs
1A46
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20232077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232077.